BlackRock
VOR icon

BlackRock’s Vor Biopharma VOR Stock Holding History

BlackRock’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.8M Buy
3,468,107
+2,673,348
+336% +$40.5M ﹤0.01% 2517
2026
Q1 		$14.2M Buy
794,759
+329,123
+71% +$4.64M ﹤0.01% 3280
2025
Q4 		$6.09M Buy
465,636
+431,106
+1,248% +$8.03M ﹤0.01% 3755
2025
Q3 		$1.68M Buy
34,530
+15,792
+84% +$635K ﹤0.01% 4146
2025
Q2 		$607K Sell
18,738
-5,487
-23% -$48.5K ﹤0.01% 4401
2025
Q1 		$348K Sell
24,225
-193
-0.8% -$4.63K ﹤0.01% 4483
2024
Q4 		$542K Buy
24,418
+35
+0.1% +$580 ﹤0.01% 4394
2024
Q3 		$341K Sell
24,383
-502
-2% -$9.15K ﹤0.01% 4413
2024
Q2 		$498K Sell
24,885
-87,488
-78% -$2.83M ﹤0.01% 4344
2024
Q1 		$5.33M Sell
112,373
-198
-0.2% -$8.69K ﹤0.01% 3643
2023
Q4 		$5.07M Buy
112,571
+7,228
+7% +$298K ﹤0.01% 3687
2023
Q3 		$4.47M Sell
105,343
-2,894
-3% -$157K ﹤0.01% 3698
2023
Q2 		$6.69M Buy
108,237
+84,857
+363% +$7.75M ﹤0.01% 3595
2023
Q1 		$2.52M Buy
23,380
+11,516
+97% +$1.28M ﹤0.01% 3944
2022
Q4 		$1.58M Sell
11,864
-10,017
-46% -$991K ﹤0.01% 4238
2022
Q3 		$1.74M Sell
21,881
-125
-0.6% -$12.3K ﹤0.01% 4257
2022
Q2 		$2.19M Sell
22,006
-45,456
-67% -$4.65M ﹤0.01% 4218
2022
Q1 		$8.15M Sell
67,462
-2,704
-4% -$460K ﹤0.01% 3691
2021
Q4 		$16.3M Buy
70,166
+13,664
+24% +$3.94M ﹤0.01% 3396
2021
Q3 		$17.7M Buy
56,502
+17,821
+46% +$5.3M ﹤0.01% 3364
2021
Q2 		$14.4M Buy
38,681
+290
+0.8% +$143K ﹤0.01% 3485
2021
Q1 		$33.1M Buy
+38,391
New +$32.5M ﹤0.01% 2890

Other funds holding VOR

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

BlackRock's VOR Position: Q2 2026 in Review

BlackRock increased its Vor Biopharma (VOR) stake by 336% in Q2 2026, buying an estimated $40.5M and bringing the position to 3,468,107 shares worth $63.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2517.

BlackRock first reported a position in VOR in Q1 2021 and has held it in 22 quarters since. 39 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • BlackRock held 3,468,107 shares of Vor Biopharma worth $63.8M as of Q2 2026.
  • BlackRock bought 2,673,348 Vor Biopharma shares in Q2 2026, an estimated $40.5M.
  • Vor Biopharma made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2517 holding.
  • BlackRock first reported a position in Vor Biopharma in Q1 2021 and has held it in 22 quarters since.
  • 39 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.